INM Stock Jumps As Amended Mentari Merger Takes Shape

InMed Pharmaceuticals Inc. stocks have been trading up by 35.77 percent amid heightened optimism from recent biotech advancement headlines.

Live Update At 09:18:10 EDT: On Wednesday, July 22, 2026 InMed Pharmaceuticals Inc. stock [NASDAQ: INM] is trending up by 35.77%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

INM is trading like a classic low-float biotech with news-driven spikes. On the daily chart, INM has been grinding in a tight band, mostly between $1.50 and $1.67 over recent weeks. That slow range says many traders were in “wait and see” mode before this latest merger update.

Intraday, it is a different story. The 5‑minute data shows INM blasting from under $2 to as high as $5.53 at the open, then washing out hard and settling back in the $2–$3 zone. That’s extreme volatility, pure and simple. For short-term traders, INM has turned into a momentum playground where level discipline and hard stops matter.

Fundamentally, INM is still a development-stage biotech. Revenue is just under $5M, but the company is running deep losses, with operating margins sharply negative and free cash flow around -$1.70M in the latest quarter. The flip side: INM shows a strong current ratio near 3.1, low debt, and price-to-book around 0.29, signaling a balance sheet that is not overleveraged. For traders, that combination — high burn, clean balance sheet, and merger optionality — often fuels news-driven squeezes.

Why Traders Are Watching The INM–Mentari Deal

Traders are locked on INM right now because the story has shifted from simple “spec biotech” to a live merger narrative. InMed Pharmaceuticals amended its previously announced all-stock merger agreement with privately held Mentari Therapeutics and filed a Form S‑4 registration statement and preliminary proxy/prospectus with the SEC. That filing is a key procedural step. It signals the deal is real enough that both sides are willing to lay it out in detail for regulators and shareholders.

The amended INM agreement does not change the headline — it sharpens the mechanics. Management clarified how the transaction will sequence, how any pre‑closing financing will affect the exchange ratio, and what tax treatment they are targeting. For active traders, those tweaks matter. Pre‑closing raises can be a double-edged sword: they keep the combined company funded, but they also change how much of the post‑deal pie current INM holders control.

Board approval from both InMed Pharmaceuticals and Mentari gives the merger political backing inside each company. But the closing target in Q4 2026 tells traders this is a long runway story. Between now and then, every S‑4 update, every financing, and every data headline from either side can swing INM sharply.

This is why the intraday tape has been so wild. The stock ripped on the merger narrative and then gave back a big chunk as day traders locked in gains. INM has turned into one of those names where you do not marry the stock — you trade the volatility and respect the risk, especially with heavy losses still on the income statement.

Conclusion

For traders studying INM, the main takeaway is simple: this is now a complex merger trade, not just a chart trade. InMed Pharmaceuticals has pushed the Mentari transaction forward by amending the all‑stock agreement and getting the Form S‑4 and preliminary proxy/prospectus on file. Clarifying transaction sequencing, exchange‑ratio impacts from any pre‑closing financing, and intended tax treatment removes some unknowns from the structure, but it also puts dilution and deal math front and center.

Financially, INM remains a small, loss‑making biotech with modest revenue and a relatively clean balance sheet. That profile, paired with the Q4 2026 closing horizon, means the stock is likely to stay news-driven. Day by day, INM will trade more on headlines, filings, and sentiment than on trailing earnings.

Traders in the Tim Sykes community focus on exactly this kind of setup: volatile, story-rich, and crowded with short-term players. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only about price action and your ability to adapt.” As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.”. With INM, that means mapping key levels, reacting, and cutting losses fast if the merger narrative turns or fresh financing pressures the stock.

This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks